Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Remodulin (treprostinil) is a prostacyclin analogue indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. It acts as a vasodilator of the pulmonary and systemic arterial vascular beds and also inhibits platelet aggregation. Remodulin improves hemodynamics, increases exercise capacity, and slows disease progression in patients with PAH. It is administered either by continuous subcutaneous or intravenous infusion and is often considered for patients who are intolerant of or have inadequate response to oral PAH therapies.
| Fact Table | |
| Formula | C23H34O5 |
| License | US FDA |
| Bioavailability | 100% (subcutaneous), 17% (oral) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Treprostinil |
| Elimination half-life | 2–4 hours |
| Dosage (Strength) | 1 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL for continuous subcutaneous or IV infusion |
| Pregnancy | Consult a doctor (Category B) |
| Brands | Remodulin, Tyvaso (inhaled), Orenitram (oral) |
| Protein binding | 91% |
| PubChem CID | 6440274 |
| MedlinePlus | a605033 |
| ChEBI | 63608 |
| ATC code | B01AC21 |
| DrugBank | DB00374 |
| KEGG | D06040 |
| Routes of administration | Subcutaneous, Intravenous, Inhaled, Oral |
Remodulin is administered as a continuous infusion via subcutaneous or intravenous routes using an infusion pump. The initial recommended dose is 1.25 ng/kg/min, titrated based on clinical response and tolerability. If initial infusion is not tolerated (e.g., due to infusion site pain), a lower starting dose of 0.625 ng/kg/min may be considered. Dosage should be adjusted in increments of 1.25 ng/kg/min per week for the first four weeks, then by 2.5 ng/kg/min per week as tolerated. The maximum tolerated dose varies by patient, with some requiring over 100 ng/kg/min.
Patients should be trained on proper administration techniques and the use of the infusion pump. Transition to intravenous infusion should be reserved for those who cannot tolerate subcutaneous administration, due to the increased risk of bloodstream infections.
Remodulin is available in sterile, preservative-free solutions containing treprostinil sodium in concentrations of 1 mg/mL, 2.5 mg/mL, 5 mg/mL, or 10 mg/mL. Inactive ingredients include sodium chloride, metacresol, sodium citrate dihydrate, citric acid monohydrate, and water for injection. pH is adjusted with sodium hydroxide and/or hydrochloric acid.
Remodulin is contraindicated in patients with known hypersensitivity to treprostinil or any of the formulation components. It should not be used in patients with pulmonary veno-occlusive disease (PVOD) or severe hepatic impairment (Child-Pugh Class C) due to the risk of drug accumulation and adverse effects.
Caution is advised in patients with hepatic or renal impairment, as treprostinil clearance may be reduced. Use in patients with bleeding disorders or who are taking anticoagulants may increase bleeding risk. Abrupt discontinuation or sudden large reductions in dose may lead to rebound pulmonary hypertension. Infusion site reactions are common with subcutaneous use; switching to intravenous administration may increase the risk of serious bloodstream infections. Patients should be regularly monitored for signs of sepsis, hypotension, or worsening PAH symptoms.
Common and serious side effects associated with Remodulin include:
Infusion site pain and reactions (e.g., erythema, swelling, abscess)
Headache
Nausea
Diarrhea
Jaw pain
Flushing
Hypotension
Edema
Bleeding episodes, including epistaxis and gastrointestinal bleeding
Sepsis (particularly with intravenous administration)
Rebound pulmonary hypertension upon abrupt discontinuation
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews